← All publications

New ACC research: tumor shrinkage hints & a new trial 🩺

Here is what is happening in adrenal cortex carcinoma care right now. 💊 Block-and-replace tumor response A case report (n=2) found that blocking cortisol with osilodrostat or metyrapone led to tumor shrinkage in metastatic ACC. This happened before chemotherapy or mitotane levels were high, suggesting these drugs might fight the cancer directly. 🧬 TP53 and CTNNB1 survival study A study of 65 resected ACCs found that TP53 and CTNNB1 mutations (changes in DNA repair and growth control genes) linked to worse survival. High mitotic activity (rapid cell division) also predicted poorer outcomes, while Ki-67 levels did not. 🧪 Ivonescimab Phase 2 trial M.D. Anderson Cancer Center is running a Phase 2 trial for ivonescimab (an immune checkpoint inhibitor) in unresectable or metastatic ACC. It is not yet recruiting, with an expected start date of February 7, 2027. Have you discussed biomarker testing with your oncology team? #AdrenocorticalCarcinoma #ACCResearch #CancerCare #MedicalUpdates AI-generated; for informational purposes only, not medical advice

Cover image: adrenal cortex carcinoma - new trials and research, Sep 30 to Oct 7, 2026